Streetbeat News

Products Services

EGRX

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced it will present a Trial in Progress on its Phase 2/3 study of intravenous amisulpride for preventing postoperative nausea and vomiting in pediatric patients at the SAMBA 2024 Annual Meeting. The study targets patients from birth to 17 years and aims to share preliminary results in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:06 pm

TSLA

Tesla Inc's (NASDAQ:TSLA) vehicle registrations in California dropped 8% in Q1, marking a second consecutive quarterly decline. Despite this, Tesla's Model Y remains the best-selling EV in the state. Overall, BEV registrations in California increased by 2.8%, with luxury brands and Rivian Automotive seeing gains. Tesla's market share within the BEV segment decreased to 55.4% from 61.8%. Globally, Tesla's deliveries fell 8.5% year-on-year in Q1, the first quarterly drop in about four years. CEO Elon Musk anticipates higher sales for the year compared to 2023.

Portfolio Pulse from Anan Ashraf

April 30, 2024 | 12:03 pm

ROKU

TTD

Roku and The Trade Desk have announced a new partnership aimed at enhancing data-driven TV streaming advertising. This collaboration will leverage Roku's extensive streaming platform and The Trade Desk's advertising technology to offer advertisers more targeted and effective advertising solutions. The partnership is expected to benefit both companies by expanding their advertising capabilities and potentially increasing their revenue from ad sales.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:01 pm

SOFI

Analysts have provided mixed ratings for SoFi Technologies (NASDAQ:SOFI) with a current average price target of $8.06, down 19.4% from the previous $10.00. The company's financial performance shows a 31.57% revenue growth, a net margin of 6.28%, but lower ROE and ROA compared to industry averages. SoFi, known for its diverse financial services, aims to be a one-stop financial solution, leveraging its acquisition of Galileo for enhanced services.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 12:00 pm

KSPI

Kaspi.kz has entered into a partnership with Alipay+ to enable QR payments for its users across China, aiming to enhance cross-border transactions and improve customer experience.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:45 am

BRTX

BioRestorative Therapies, identified by its stock symbol BRTX, has entered into a commercial agreement with Cartessa, a provider of medical aesthetics technology. This partnership aims to leverage Cartessa's distribution network to enhance the market reach of BioRestorative Therapies' products, potentially increasing BRTX's revenue and market presence in the medical aesthetics sector.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:42 am

VRPX

Virpax Pharmaceuticals announced results from a maximum tolerated dose study of Probudur in Sprague-Dawley rats. Probudur, a long-acting liposomal bupivacaine formulation, aims to reduce or eliminate opioid use after surgery.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:39 am

MRVI

TriLink BioTechnologies has entered into a non-exclusive license and supply agreement with Lonza for the use of its CleanCap mRNA capping technology. This partnership aims to enhance the development and manufacturing capabilities for mRNA-based therapies.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:38 am

DARE

XOMA

Xoma has acquired an economic interest in three women's health assets from Daré Bioscience for an upfront payment of $22M, including interests in Ovaprene and Sildenafil Cream. Organon has initiated XACIATO commercial activities, and Bayer HealthCare holds exclusive rights to Ovaprene in the U.S.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 11:36 am

DJT

RDDT

The upcoming U.S. presidential election in November is expected to temporarily slow down the IPO market, with market advisors and investors predicting a brief pause around the election date. Ernst & Young and Deloitte & Touche LLP suggest some IPOs may adjust their timing, either moving up their schedules or delaying until late 2024 or 2025. The IPO market has seen over $13.7 billion raised in the U.S. this year, though it remains 92% lower than the record-breaking year of 2021. Companies like Trump Media & Technology Group and Reddit Inc are navigating the complexities of this period, facing volatility and market scrutiny.

Portfolio Pulse from Michael Cohen

April 30, 2024 | 11:36 am